Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study

Introduction: There is no clear relationship between type 2 diabetes mellitus and lung function decline; it is also unclear whether the type of treatment can modify spirometric variables and levels of inflammatory biomarkers. Objectives: To compare pulmonary function in patients with type 2 diabetes...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2016
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23542
Acceso en línea:
https://doi.org/10.7705/biomedica.v36i3.2752
https://repository.urosario.edu.co/handle/10336/23542
Palabra clave:
C reactive protein
Insulin
Interleukin 6
Tumor necrosis factor
Chemistry
Complication
Cross-sectional study
Forced expiratory volume
Human
Immunology
Lung
Metabolism
Non insulin dependent diabetes mellitus
Pathophysiology
Physiology
Procedures
Spirometry
C-Reactive Protein
Cross-Sectional Studies
Forced Expiratory Volume
Humans
Insulin
Interleukin-6
Lung
Spirometry
Tumor Necrosis Factor-alpha
Diabetes mellitus
Inflammation
Insulins
Lung
Metformin
human
IL6 protein
Type 2
Diabetes Mellitus
Rights
License
Abierto (Texto Completo)
id EDOCUR2_9b4f475e1cf09aae6221488302c5d543
oai_identifier_str oai:repository.urosario.edu.co:10336/23542
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 71b9c43b-b265-4671-82aa-54e14229db66-130a8413c-dc6d-4430-a4ac-2e0c9b241365-1791481066002020-05-26T00:02:56Z2020-05-26T00:02:56Z2016Introduction: There is no clear relationship between type 2 diabetes mellitus and lung function decline; it is also unclear whether the type of treatment can modify spirometric variables and levels of inflammatory biomarkers. Objectives: To compare pulmonary function in patients with type 2 diabetes treated with an insulin-sensitizing agent (metformin) and in those treated with secretagogues, as well as combined with insulin, and to evaluate differences in inflammatory biomarkers between treatment groups. Material and methods: We conducted a cross-sectional analytic study in 196 diabetic patients with type 2 diabetic mellitus. Spirometric variables and levels of inflammatory biomarkers (ferritin, fibrinogen, C-reactive protein, interleukin 6, tumor necrosis factor-alpha), were obtained. Residual values (observed minus expected) for forced vital capacity and for forced expiratory volume were calculated and compared between treatment types. Differences in median levels of biomarkers were also compared. Results: After adjustment by known determinants of lung function, and by the control and duration of type 2 diabetes, patients treated with the insulin-sensitizing agent had statistically significant lower differences against expected values for forced vital capacity compared with secretagogues (-212.1 ml vs 270.2 ml, p=0.039), as well as for forced expiratory volume, but without statistical significance (-133.2 mL vs -174.8 mL, p>0.05). In the group of patients treated with the insulin-sensitizing agent, ferritin and tumor necrosis factor-alpha levels were lower (p less than 0.01). Conclusion: This study supports the hypothesis that insulin-sensitizing agents appear to be associated with less deterioration of lung function and less systemic inflammation in type 2 diabetes. The present study serves to formulate new hypothesis and research projects.application/pdfhttps://doi.org/10.7705/biomedica.v36i3.2752https://repository.urosario.edu.co/handle/10336/23542engInstituto Nacional de Salud284No. 2276BiomedicaVol. 36Biomedica, Vol.36, No.2 (2016); pp. 276-284https://www.scopus.com/inward/record.uri?eid=2-s2.0-84980316423&doi=10.7705%2fbiomedica.v36i3.2752&partnerID=40&md5=b4ded2c237c898540af38a73793844f8Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURC reactive proteinInsulinInterleukin 6Tumor necrosis factorChemistryComplicationCross-sectional studyForced expiratory volumeHumanImmunologyLungMetabolismNon insulin dependent diabetes mellitusPathophysiologyPhysiologyProceduresSpirometryC-Reactive ProteinCross-Sectional StudiesForced Expiratory VolumeHumansInsulinInterleukin-6LungSpirometryTumor Necrosis Factor-alphaDiabetes mellitusInflammationInsulinsLungMetforminhumanIL6 proteinType 2Diabetes MellitusPharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional studyTratamiento farmacológico y deterioro de la función pulmonar en pacientes con diabetes de tipo 2: Un estudio de corte transversalarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Vargas, Henry A.Rondón, MartínDennis Verano, Rodolfo José10336/23542oai:repository.urosario.edu.co:10336/235422022-05-02 07:37:14.551994https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study
dc.title.TranslatedTitle.spa.fl_str_mv Tratamiento farmacológico y deterioro de la función pulmonar en pacientes con diabetes de tipo 2: Un estudio de corte transversal
title Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study
spellingShingle Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study
C reactive protein
Insulin
Interleukin 6
Tumor necrosis factor
Chemistry
Complication
Cross-sectional study
Forced expiratory volume
Human
Immunology
Lung
Metabolism
Non insulin dependent diabetes mellitus
Pathophysiology
Physiology
Procedures
Spirometry
C-Reactive Protein
Cross-Sectional Studies
Forced Expiratory Volume
Humans
Insulin
Interleukin-6
Lung
Spirometry
Tumor Necrosis Factor-alpha
Diabetes mellitus
Inflammation
Insulins
Lung
Metformin
human
IL6 protein
Type 2
Diabetes Mellitus
title_short Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study
title_full Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study
title_fullStr Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study
title_full_unstemmed Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study
title_sort Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: A cross-sectional study
dc.subject.keyword.spa.fl_str_mv C reactive protein
Insulin
Interleukin 6
Tumor necrosis factor
Chemistry
Complication
Cross-sectional study
Forced expiratory volume
Human
Immunology
Lung
Metabolism
Non insulin dependent diabetes mellitus
Pathophysiology
Physiology
Procedures
Spirometry
C-Reactive Protein
Cross-Sectional Studies
Forced Expiratory Volume
Humans
Insulin
Interleukin-6
Lung
Spirometry
Tumor Necrosis Factor-alpha
Diabetes mellitus
Inflammation
Insulins
Lung
Metformin
topic C reactive protein
Insulin
Interleukin 6
Tumor necrosis factor
Chemistry
Complication
Cross-sectional study
Forced expiratory volume
Human
Immunology
Lung
Metabolism
Non insulin dependent diabetes mellitus
Pathophysiology
Physiology
Procedures
Spirometry
C-Reactive Protein
Cross-Sectional Studies
Forced Expiratory Volume
Humans
Insulin
Interleukin-6
Lung
Spirometry
Tumor Necrosis Factor-alpha
Diabetes mellitus
Inflammation
Insulins
Lung
Metformin
human
IL6 protein
Type 2
Diabetes Mellitus
dc.subject.keyword.eng.fl_str_mv human
IL6 protein
Type 2
Diabetes Mellitus
description Introduction: There is no clear relationship between type 2 diabetes mellitus and lung function decline; it is also unclear whether the type of treatment can modify spirometric variables and levels of inflammatory biomarkers. Objectives: To compare pulmonary function in patients with type 2 diabetes treated with an insulin-sensitizing agent (metformin) and in those treated with secretagogues, as well as combined with insulin, and to evaluate differences in inflammatory biomarkers between treatment groups. Material and methods: We conducted a cross-sectional analytic study in 196 diabetic patients with type 2 diabetic mellitus. Spirometric variables and levels of inflammatory biomarkers (ferritin, fibrinogen, C-reactive protein, interleukin 6, tumor necrosis factor-alpha), were obtained. Residual values (observed minus expected) for forced vital capacity and for forced expiratory volume were calculated and compared between treatment types. Differences in median levels of biomarkers were also compared. Results: After adjustment by known determinants of lung function, and by the control and duration of type 2 diabetes, patients treated with the insulin-sensitizing agent had statistically significant lower differences against expected values for forced vital capacity compared with secretagogues (-212.1 ml vs 270.2 ml, p=0.039), as well as for forced expiratory volume, but without statistical significance (-133.2 mL vs -174.8 mL, p>0.05). In the group of patients treated with the insulin-sensitizing agent, ferritin and tumor necrosis factor-alpha levels were lower (p less than 0.01). Conclusion: This study supports the hypothesis that insulin-sensitizing agents appear to be associated with less deterioration of lung function and less systemic inflammation in type 2 diabetes. The present study serves to formulate new hypothesis and research projects.
publishDate 2016
dc.date.created.spa.fl_str_mv 2016
dc.date.accessioned.none.fl_str_mv 2020-05-26T00:02:56Z
dc.date.available.none.fl_str_mv 2020-05-26T00:02:56Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.7705/biomedica.v36i3.2752
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/23542
url https://doi.org/10.7705/biomedica.v36i3.2752
https://repository.urosario.edu.co/handle/10336/23542
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 284
dc.relation.citationIssue.none.fl_str_mv No. 2
dc.relation.citationStartPage.none.fl_str_mv 276
dc.relation.citationTitle.none.fl_str_mv Biomedica
dc.relation.citationVolume.none.fl_str_mv Vol. 36
dc.relation.ispartof.spa.fl_str_mv Biomedica, Vol.36, No.2 (2016); pp. 276-284
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-84980316423&doi=10.7705%2fbiomedica.v36i3.2752&partnerID=40&md5=b4ded2c237c898540af38a73793844f8
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Instituto Nacional de Salud
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167440964190209